跳至主要内容
临床试验/NCT03394859
NCT03394859已完成不适用

Electronic Medical Records and Genomics (eMERGE) Phase III

Vanderbilt University Medical Center0 个研究点目标入组 25,380 人开始时间: 2015年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25,380
主要终点
Impact of return of clinically actionable results on patient treatment

研究概览

简要总结

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes. The genetic results will be returned to participants and outcomes tracked through the electronic health records.

详细描述

The Electronic Medical Records and Genomics (eMERGE) Network is a National Human Genome Research Institute (NHGRI)-funded consortium tasked with developing methods and best practices for utilization of the electronic medical record (EMR) as a tool for genomic research. Phase III is focused on returning actionable gene variants to patients and measuring clinical outcomes. Ultimately, eMERGE hopes its efforts will result in improvements in health care, through safer and more effective prescription methodology, augmentation of primary and secondary prevention strategies, and enhanced understanding of the biology of disease.

eMERGE is composed of 10 clinical sites [ Childrens Hospital of Pennsylvania (CHOP); Cincinnati Children's Medical Center (CCHMC); Columbia University; Geisinger; Kaiser Permanente Washington with Washington University and the Fred Hutchinson Cancer Research Center; Harvard University; Mayo Clinic; Meharry Medical College; Northwestern University; Vanderbilt University Medical center (VUMC)], one non clinical site: Marshfield Clinic, two sequencing centers [Baylor college of Medicine; Partners Healthcare with Broad Institute], a Coordinating Center (VUMC), and the NHGRI. More information on the eMERGE Network can be found at www.gwas.org.

Each sites' research study is tailored to their specific interests. An eMERGE specific sequencing panel was designed and ran on participants covering 109 genes and 1551 Single Nucleotide Variants (SNVs), of which 68 genes and 14 SNVs are clinically actionable and are being returned to patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Day 至 120 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 1 day old
  • Vital status: Alive

排除标准

  • 未提供

结局指标

主要结局

Impact of return of clinically actionable results on patient treatment

时间窗: Six months post return of results

The network will abstract data from patient electronic health records (EHR) six months after clinically actionable results have been returned to the patients and providers. The Network will determine changes in medication or treatments after return of the sequencing results. Outcome measures on patients receiving both positive and negative results will be analyzed.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Josh Peterson

Associate Professor of Biomedical Informatics

Vanderbilt University Medical Center

相似试验

进行中(未招募)
不适用
Phase 3, multicenter, multi-national, open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluded central venous access devices (sonoma-3) - NDCentral venous access device withdrawal occlusionMedDRA version: 9.1Level: SOCClassification code 10042613Term: Surgical and medical procedures
EUCTR2006-000545-19-ITVELO800
进行中(未招募)
3 期
The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 cycles of temozolomide after chemoradiotherapy, or continue monthly treatment until disease progressioCancer - BrainGlioblastoma
ACTRN12620000048987HMRC Clinical Trials Centre (CTC), University of Sydney338
进行中(未招募)
1 期
Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut SyndromesDravet and Lennox-Gastaut SyndromesMedDRA version: 20.0Level: LLTClassification code: 10073682Term: Dravet syndrome Class: 10010331MedDRA version: 20.1Level: PTClassification code: 10048816Term: Lennox-Gastaut syndrome Class: 100000004852
CTIS2022-502802-34-00Takeda Development Center Americas Inc.377
已完成
3 期
Prevention of Cholera from the use of experimental oral cholera vaccine (Euvichol-Plus)
CTRI/2021/08/035344Techinvention lifecare Pvt Ltd416
进行中(未招募)
1 期
A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effect on symptoms with idiopathic Parkinson's disease - n/aIdiopathic Parkinson's disease
EUCTR2004-002650-59-GBSCHWARZ BIOSCIENCES130